Cargando…

Delayed Administration of a Bio-Engineered Zinc-Finger VEGF-A Gene Therapy Is Neuroprotective and Attenuates Allodynia Following Traumatic Spinal Cord Injury

Following spinal cord injury (SCI) there are drastic changes that occur in the spinal microvasculature, including ischemia, hemorrhage, endothelial cell death and blood-spinal cord barrier disruption. Vascular endothelial growth factor-A (VEGF-A) is a pleiotropic factor recognized for its pro-angiog...

Descripción completa

Detalles Bibliográficos
Autores principales: Figley, Sarah A., Liu, Yang, Karadimas, Spyridon K., Satkunendrarajah, Kajana, Fettes, Peter, Spratt, S. Kaye, Lee, Gary, Ando, Dale, Surosky, Richard, Giedlin, Martin, Fehlings, Michael G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028194/
https://www.ncbi.nlm.nih.gov/pubmed/24846143
http://dx.doi.org/10.1371/journal.pone.0096137
_version_ 1782317041205641216
author Figley, Sarah A.
Liu, Yang
Karadimas, Spyridon K.
Satkunendrarajah, Kajana
Fettes, Peter
Spratt, S. Kaye
Lee, Gary
Ando, Dale
Surosky, Richard
Giedlin, Martin
Fehlings, Michael G.
author_facet Figley, Sarah A.
Liu, Yang
Karadimas, Spyridon K.
Satkunendrarajah, Kajana
Fettes, Peter
Spratt, S. Kaye
Lee, Gary
Ando, Dale
Surosky, Richard
Giedlin, Martin
Fehlings, Michael G.
author_sort Figley, Sarah A.
collection PubMed
description Following spinal cord injury (SCI) there are drastic changes that occur in the spinal microvasculature, including ischemia, hemorrhage, endothelial cell death and blood-spinal cord barrier disruption. Vascular endothelial growth factor-A (VEGF-A) is a pleiotropic factor recognized for its pro-angiogenic properties; however, VEGF has recently been shown to provide neuroprotection. We hypothesized that delivery of AdV-ZFP-VEGF – an adenovirally delivered bio-engineered zinc-finger transcription factor that promotes endogenous VEGF-A expression – would result in angiogenesis, neuroprotection and functional recovery following SCI. This novel VEGF gene therapy induces the endogenous production of multiple VEGF-A isoforms; a critical factor for proper vascular development and repair. Briefly, female Wistar rats – under cyclosporin immunosuppression – received a 35 g clip-compression injury and were administered AdV-ZFP-VEGF or AdV-eGFP at 24 hours post-SCI. qRT-PCR and Western Blot analysis of VEGF-A mRNA and protein, showed significant increases in VEGF-A expression in AdV-ZFP-VEGF treated animals (p<0.001 and p<0.05, respectively). Analysis of NF200, TUNEL, and RECA-1 indicated that AdV-ZFP-VEGF increased axonal preservation (p<0.05), reduced cell death (p<0.01), and increased blood vessels (p<0.01), respectively. Moreover, AdV-ZFP-VEGF resulted in a 10% increase in blood vessel proliferation (p<0.001). Catwalk™ analysis showed AdV-ZFP-VEGF treatment dramatically improves hindlimb weight support (p<0.05) and increases hindlimb swing speed (p<0.02) when compared to control animals. Finally, AdV-ZFP-VEGF administration provided a significant reduction in allodynia (p<0.01). Overall, the results of this study indicate that AdV-ZFP-VEGF administration can be delivered in a clinically relevant time-window following SCI (24 hours) and provide significant molecular and functional benefits.
format Online
Article
Text
id pubmed-4028194
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40281942014-05-21 Delayed Administration of a Bio-Engineered Zinc-Finger VEGF-A Gene Therapy Is Neuroprotective and Attenuates Allodynia Following Traumatic Spinal Cord Injury Figley, Sarah A. Liu, Yang Karadimas, Spyridon K. Satkunendrarajah, Kajana Fettes, Peter Spratt, S. Kaye Lee, Gary Ando, Dale Surosky, Richard Giedlin, Martin Fehlings, Michael G. PLoS One Research Article Following spinal cord injury (SCI) there are drastic changes that occur in the spinal microvasculature, including ischemia, hemorrhage, endothelial cell death and blood-spinal cord barrier disruption. Vascular endothelial growth factor-A (VEGF-A) is a pleiotropic factor recognized for its pro-angiogenic properties; however, VEGF has recently been shown to provide neuroprotection. We hypothesized that delivery of AdV-ZFP-VEGF – an adenovirally delivered bio-engineered zinc-finger transcription factor that promotes endogenous VEGF-A expression – would result in angiogenesis, neuroprotection and functional recovery following SCI. This novel VEGF gene therapy induces the endogenous production of multiple VEGF-A isoforms; a critical factor for proper vascular development and repair. Briefly, female Wistar rats – under cyclosporin immunosuppression – received a 35 g clip-compression injury and were administered AdV-ZFP-VEGF or AdV-eGFP at 24 hours post-SCI. qRT-PCR and Western Blot analysis of VEGF-A mRNA and protein, showed significant increases in VEGF-A expression in AdV-ZFP-VEGF treated animals (p<0.001 and p<0.05, respectively). Analysis of NF200, TUNEL, and RECA-1 indicated that AdV-ZFP-VEGF increased axonal preservation (p<0.05), reduced cell death (p<0.01), and increased blood vessels (p<0.01), respectively. Moreover, AdV-ZFP-VEGF resulted in a 10% increase in blood vessel proliferation (p<0.001). Catwalk™ analysis showed AdV-ZFP-VEGF treatment dramatically improves hindlimb weight support (p<0.05) and increases hindlimb swing speed (p<0.02) when compared to control animals. Finally, AdV-ZFP-VEGF administration provided a significant reduction in allodynia (p<0.01). Overall, the results of this study indicate that AdV-ZFP-VEGF administration can be delivered in a clinically relevant time-window following SCI (24 hours) and provide significant molecular and functional benefits. Public Library of Science 2014-05-20 /pmc/articles/PMC4028194/ /pubmed/24846143 http://dx.doi.org/10.1371/journal.pone.0096137 Text en © 2014 Figley et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Figley, Sarah A.
Liu, Yang
Karadimas, Spyridon K.
Satkunendrarajah, Kajana
Fettes, Peter
Spratt, S. Kaye
Lee, Gary
Ando, Dale
Surosky, Richard
Giedlin, Martin
Fehlings, Michael G.
Delayed Administration of a Bio-Engineered Zinc-Finger VEGF-A Gene Therapy Is Neuroprotective and Attenuates Allodynia Following Traumatic Spinal Cord Injury
title Delayed Administration of a Bio-Engineered Zinc-Finger VEGF-A Gene Therapy Is Neuroprotective and Attenuates Allodynia Following Traumatic Spinal Cord Injury
title_full Delayed Administration of a Bio-Engineered Zinc-Finger VEGF-A Gene Therapy Is Neuroprotective and Attenuates Allodynia Following Traumatic Spinal Cord Injury
title_fullStr Delayed Administration of a Bio-Engineered Zinc-Finger VEGF-A Gene Therapy Is Neuroprotective and Attenuates Allodynia Following Traumatic Spinal Cord Injury
title_full_unstemmed Delayed Administration of a Bio-Engineered Zinc-Finger VEGF-A Gene Therapy Is Neuroprotective and Attenuates Allodynia Following Traumatic Spinal Cord Injury
title_short Delayed Administration of a Bio-Engineered Zinc-Finger VEGF-A Gene Therapy Is Neuroprotective and Attenuates Allodynia Following Traumatic Spinal Cord Injury
title_sort delayed administration of a bio-engineered zinc-finger vegf-a gene therapy is neuroprotective and attenuates allodynia following traumatic spinal cord injury
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028194/
https://www.ncbi.nlm.nih.gov/pubmed/24846143
http://dx.doi.org/10.1371/journal.pone.0096137
work_keys_str_mv AT figleysaraha delayedadministrationofabioengineeredzincfingervegfagenetherapyisneuroprotectiveandattenuatesallodyniafollowingtraumaticspinalcordinjury
AT liuyang delayedadministrationofabioengineeredzincfingervegfagenetherapyisneuroprotectiveandattenuatesallodyniafollowingtraumaticspinalcordinjury
AT karadimasspyridonk delayedadministrationofabioengineeredzincfingervegfagenetherapyisneuroprotectiveandattenuatesallodyniafollowingtraumaticspinalcordinjury
AT satkunendrarajahkajana delayedadministrationofabioengineeredzincfingervegfagenetherapyisneuroprotectiveandattenuatesallodyniafollowingtraumaticspinalcordinjury
AT fettespeter delayedadministrationofabioengineeredzincfingervegfagenetherapyisneuroprotectiveandattenuatesallodyniafollowingtraumaticspinalcordinjury
AT sprattskaye delayedadministrationofabioengineeredzincfingervegfagenetherapyisneuroprotectiveandattenuatesallodyniafollowingtraumaticspinalcordinjury
AT leegary delayedadministrationofabioengineeredzincfingervegfagenetherapyisneuroprotectiveandattenuatesallodyniafollowingtraumaticspinalcordinjury
AT andodale delayedadministrationofabioengineeredzincfingervegfagenetherapyisneuroprotectiveandattenuatesallodyniafollowingtraumaticspinalcordinjury
AT suroskyrichard delayedadministrationofabioengineeredzincfingervegfagenetherapyisneuroprotectiveandattenuatesallodyniafollowingtraumaticspinalcordinjury
AT giedlinmartin delayedadministrationofabioengineeredzincfingervegfagenetherapyisneuroprotectiveandattenuatesallodyniafollowingtraumaticspinalcordinjury
AT fehlingsmichaelg delayedadministrationofabioengineeredzincfingervegfagenetherapyisneuroprotectiveandattenuatesallodyniafollowingtraumaticspinalcordinjury